IP Library Granted Patent US 10,228,374
Granted Patent B2
US 10,228,374 · App. 15/500,478 · Granted Mar 12, 2019

Antibodies with high affinity for alpha-Klotho

Inventors: Sachdev S. Sidhu (Toronto, CA); Sarah L. Barker (Toronto, CA); Orson W. Moe (Dallas, TX); Makoto Kuro-o (Dallas, TX)
Assignees: The Governng Council of the University of Toronto; Board of Regents, The University of Texas System
G01N33/573C07K14/71C07K16/28C07K16/40C12N9/2402C12Y302/01031G01N33/6872C07K2317/51C07K2317/515C07K2317/56C07K2317/565C07K2317/92G01N2333/924G01N2800/347G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,228,374
App. No.
15/500,478
Granted
Mar 12, 2019
Kind
B2
Abstract

An antibody and/or binding fragment thereof, wherein the antibody and/or binding fragment thereof specifically binds to an epitope of a αKlotho polypeptide, optionally a folded αKiotho or optionally with a dissociation constant (K D ) of about 2 nM or less, as measured by competitive ELISA assay, methods 0 of making and using to diagnose kidney diseases.

Claims (27)

1. An antibody and/or binding fragment thereof that specifically binds to an epitope of αKlotho polypeptide, wherein said antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising complementarity determining regions CDR-L1, CDR-L2 and CDR-L3 and the heavy chain variable region comprising complementarity determining regions CDR-H1, CDR-H2 and CDR-H3, with the amino acid sequences of said CDRs consisting of the sequences set forth below:

CDR-L1

(SEQ ID NO: 9)

QSVSSA;

CDR-L2:

(SEQ ID NO: 10)

SAS;

CDR-L3:

(SEQ ID NO: 5)

QQAGYSPIT;

CDR-H1:

(SEQ ID NO: 6)

GFNISYYS;

CDR-H2:

(SEQ ID NO: 7)

ISPSYGYTS;

and

CDR-H3:

(SEQ ID NO: 8)

ARYYVYASHGWAGYGM.

2. The antibody and/or binding fragment thereof of claim 1 , wherein the antibody and/or binding fragment thereof comprises a light chain with the amino acid sequence set forth in SEQ ID NO: 11 and/or comprises a heavy chain with the amino acid sequence set forth in SEQ ID NO:12.

3. The antibody and/or binding fragment thereof of claim 1 , wherein the antibody and/or binding fragment thereof is selected from the group consisting of a monoclonal antibody, an immunoglobulin molecule, a Fab, a Fab′, a F(ab)2, a F(ab′)2, a Fv, a disulfide-linked Fv, a scFv, a disulfide-linked scFv, a single-chain domain antibody, a diabody, a dimer, a minibody, a bispecific antibody fragment, a chimeric antibody, a humanized antibody and a polyclonal antibody.

4. The antibody and/or binding fragment thereof of claim 1 , wherein the folded αKlotho polypeptide is soluble αKlotho polypeptide found in urine, plasma, and/or serum.

5. The antibody and/or binding fragment thereof of claim 1 , wherein the antibody and/or binding fragment thereof binds a complex comprising folded αKlotho polypeptide and a fibroblast growth factor (FGF) receptor, and optionally FGFR1c.

6. The antibody and/or binding fragment of claim 1 , wherein the antibody and/or binding fragment is labeled with a detectable tag.

7. An antibody complex comprising the antibody and/or binding fragment thereof of claim 1 and αKlotho, optionally further comprising FGFR1c.

8. A composition or kit comprising the antibody and/or binding fragment thereof of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2017
From: SIDHU, SACHDEV; BARKER, SARAH
To: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
Reel/Frame 043028/0676 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2017
From: MOE, ORSON; KURO-O, MAKOTO
To: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Reel/Frame 042878/0127 →
Continuity (2)
Provisional Application 62031477 · Jul 31, 2014
Related Publication 20170219582A1 · Aug 3, 2017